Quarterly report pursuant to Section 13 or 15(d)

Supplemental Information to Condensed Consolidated Statements of Cash Flows (Detail)

v3.21.2
Supplemental Information to Condensed Consolidated Statements of Cash Flows (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
[3]
Sep. 30, 2021
Sep. 30, 2020
Schedule Of Cash Flow Supplemental [Line Items]            
Cash paid for interest         $ 89,834 $ 53,364
Cash paid (refunds received) for income taxes, net         (136,937) (108,776)
Cash deposited in restricted accounts [1] $ 7,300       7,300  
Noncash investing and financing activities:            
Change in accounts payable and accrued expenses for the acquisition of theatre properties and equipment [2]         (2,409) (7,933)
Investment in NCM – receipt of common units (see Note 9)         10,237 3,620
Adjustment to accrued dividends on unvested restricted stock unit awards   $ 2   $ 256 2 (257)
NCM            
Noncash investing and financing activities:            
Interest expense - NCM (see Note 9) $ (5,926)   $ (5,901)   $ (17,723) $ (17,726)
[1] Represents cash deposited in a collateral account during the period to support the issuance of letters of credit to lenders. See further discussion at Note 7.
[2] Additions to theatre properties and equipment included in accounts payable as of September 30, 2021 and December 31, 2020 were $25,841 and $28,250, respectively.
[3] On March 20, 2020 the Company paid a $0.36 dividend per common share to stockholders of record on March 6, 2020. Additionally, the Company accrued dividends on outstanding unvested restricted stock units.